The global spine biologics market is on pace to have a 17.51% compound annual growth rate from 2024 to 2034, according to a Jan. 31 news release from ResearchandMarkets.com.
Biologics
Stem cell therapies can be effective for treating discogenic low back pain, according to a study published in the January 2025 issue of the International Journal of Spine Surgery.
Jamie Antoine, MD, of Seattle-based Proliance Surgeons performed the first case using CartiHeal's Agili-C implant in Washington state, according to a Jan. 27 LinkedIn post.
Acuitive Technologies named Wayne Berberian, MD, as its chief medical officer, according to a Jan. 27 news release.
LifeNet Health and Johnson & Johnson MedTech launched the PliaFX Flo demineralized bone matrix.
Advertisement
SurGenTec earned FDA 510(k) clearance for its OsteoFlo HydroFiber to be used as a stand-alone equivalent to autografts in spine surgeries.
Royal Biologics and Fair Winds Medical partnered to distribute spine and orthopedic biologics, according to a Jan. 16 news release.
From new studies and milestones, here are seven key updates in orthobiologics since Nov. 13.
Ventris Medical earned FDA 510(k) clearance for its Backpack bone graft containment system, according to a Jan. 9 news release.
Medtronic and Kuros Biosciences signed a strategic agreement to support sales of the MagnetOs bone graft technology.